Chicago Equity Partners LLC reduced its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 64,315 shares of the biotechnology company’s stock after selling 990 shares during the period. Chicago Equity Partners LLC owned 0.15% of United Therapeutics Corporation worth $8,344,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Focused Wealth Management Inc boosted its stake in United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after buying an additional 140 shares in the last quarter. Advisory Services Network LLC purchased a new stake in United Therapeutics Corporation during the first quarter worth $147,000. Daiwa Securities Group Inc. boosted its stake in United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after buying an additional 200 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in United Therapeutics Corporation during the first quarter worth $204,000. Finally, Eagle Global Advisors LLC purchased a new stake in United Therapeutics Corporation during the second quarter worth $206,000.

United Therapeutics Corporation (UTHR) opened at 130.80 on Friday. The firm’s 50-day moving average is $130.07 and its 200-day moving average is $132.13. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The stock has a market capitalization of $5.68 billion, a price-to-earnings ratio of 15.17 and a beta of 1.51.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. The business had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the company earned $4.42 earnings per share. Analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “United Therapeutics Corporation (UTHR) Position Decreased by Chicago Equity Partners LLC” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-position-decreased-by-chicago-equity-partners-llc/1535946.html.

A number of analysts have recently weighed in on the stock. Jefferies Group LLC restated a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a report on Thursday, June 8th. BidaskClub cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. UBS AG restated a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Finally, Zacks Investment Research lowered shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $134.50.

In other news, CEO Martine A. Rothblatt sold 1,238 shares of the stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $130.65, for a total value of $161,744.70. Following the completion of the sale, the chief executive officer now directly owns 2,307 shares of the company’s stock, valued at $301,409.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,240 shares of the stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $129.60, for a total value of $160,704.00. Following the completion of the sale, the chief executive officer now directly owns 1,380 shares of the company’s stock, valued at $178,848. The disclosure for this sale can be found here. Insiders sold 23,371 shares of company stock valued at $3,046,727 over the last ninety days. 7.80% of the stock is currently owned by corporate insiders.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.